Shanghai Fosun Pharma, a China-based company, has announced that it will jointly invest $240m with Pramerica-Fosun China Opportunity Fund to purchase around 95.6% share of Israel-based Alma Lasers.
Alma Lasers is a global medical and cosmetic energy-based, including lights, laser, radio frequency and ultrasound, device manufacturer and has developed world-class R & D capabilities in the medical and cosmetic energy-based device manufacturing field.
The acquisition of shares forms part of Fosun Pharma's strategy of growing its global business.
The medical devices business of the company will continue its strategy of moving from product distribution to R&D and manufacturing, and gain a leading position in the international aesthetic medical device market segment, according to Fosun Pharma.
Fosun Pharma chairman Qiyu Chen said that the company will continue to support Alma's global expansion.
"Fosun Pharma will build on Alma's strength and be committed to developing a high-end medical device research, manufacturing platform," Chen added.
